Biocentury coverage points to Q’s proposed €5 billion cross-sector growth fund as a potential tool to narrow Europe’s biotech capital gap. The concept is aimed at increasing the availability of “homegrown” growth capital for European life science companies, which have historically relied more heavily on US and late-stage funding streams. For European management teams, the key question is execution—whether the fund can support enough sustained growth-stage financing to reduce funding discontinuities that can delay pivotal trials and scale-up plans.